2. Search Result
Search Result
Results for "

T-type

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

4

Peptides

1

Natural
Products

5

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10035
    TTA-P2

    T-type calcium channel inhibitor

    		 Calcium Channel Neurological Disease
    TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .
    TTA-P2
  • HY-50707
    (Rac)-TTA-P2

    (Rac)-T-type calcium channel inhibitor

    		 Others Neurological Disease
    (Rac)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .
    (Rac)-TTA-P2
  • HY-10035A
    (R)-TTA-P2

    		Others Neurological Disease
    (R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .
    (R)-TTA-P2
  • HY-147708
    T-Type calcium channel inhibitor 2

    		Calcium Channel Cancer
    T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC50s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC50s of 5.0, 6.4 µM, respectively .
    <em>T-Type</em> calcium channel inhibitor 2
  • HY-150539
    IAB15

    		Calcium Channel Neurological Disease
    IAB15 is a potent T-type calcium channel inhibitor. IAB15 can be used for epilepsy research .
    IAB15
  • HY-150541
    IAA65

    		Calcium Channel Neurological Disease
    IAA65 is a potent T-type calcium channel inhibitor with a IC50 value of 18.9 µM. IAA65 can be used for epilepsy research .
    IAA65
  • HY-P5869
    Kurtoxin

    		Calcium Channel Sodium Channel Neurological Disease
    Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca 2+ channel gating inhibitor with a Kd of 15 nM for Cav3.1 (α1G T-type) Ca 2+ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca 2+ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na + channel .
    Kurtoxin
  • HY-10955
    TTA-P1

    		Calcium Channel Neurological Disease
    TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy .
    TTA-P1
  • HY-154832
    Cav 3.2 inhibitor 4

    		Calcium Channel Cardiovascular Disease
    Cav 3.2 inhibitor 4 (compound 21) is a potent, peripherally restricted, selective T-type calcium channel (Cav3.2) inhibitor, with an IC50 of 0.6 μM. Cav 3.2 inhibitor 4 can be used for the research of atrial fibrillation .
    Cav 3.2 inhibitor 4
  • HY-151450
    Cav 3.2 inhibitor 1

    		Calcium Channel Neurological Disease Inflammation/Immunology
    Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain .
    Cav 3.2 inhibitor 1
  • HY-14232
    TTA-A8

    		Calcium Channel Neurological Disease
    TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .
    TTA-A8
  • HY-A0092
    Trimethadione

    3,5,5,-Trimethyloxazolidine-2,4-dione

    		 Calcium Channel Neurological Disease
    Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects .
    Trimethadione
  • HY-B0768A
    Lomerizine dihydrochloride

    KB-2796

    		 Calcium Channel Neurological Disease
    Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
    Lomerizine dihydrochloride
  • HY-151452
    Cav 3.2 inhibitor 3

    		Calcium Channel Neurological Disease
    Cav 3.2 inhibitor 3 (Compound 4) is a potent Cav3.2 T-type Ca 2+ channel inhibitor with an IC50 of 0.1534 μM, and has little binding affinity to D2 receptors .
    Cav 3.2 inhibitor 3
  • HY-15553A
    Mibefradil dihydrochloride
    Maximum Cited Publications
    9 Publications Verification

    Ro 40-5967 dihydrochloride

    		 Calcium Channel Cardiovascular Disease Cancer
    Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca 2+ channels (IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively) .
    Mibefradil dihydrochloride
  • HY-15553
    Mibefradil

    Ro 40-5967

    		 Calcium Channel Cardiovascular Disease
    Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca 2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively .
    Mibefradil
  • HY-50722
    NNC 55-0396
    4 Publications Verification

    NNC 55-0396 dihydrochloride

    		 Calcium Channel Cardiovascular Disease Neurological Disease
    NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research .
    NNC 55-0396
  • HY-147638
    MONIRO-1

    		Calcium Channel Neurological Disease
    MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively .
    MONIRO-1
  • HY-12502
    Efonidipine

    NZ-105; (±)-Efonidipine

    		 Calcium Channel Cardiovascular Disease
    Efonidipine(NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).
    Efonidipine
  • HY-12502B
    Efonidipine hydrochloride

    NZ-105 hydrochloride

    		 Calcium Channel Cardiovascular Disease
    Efonidipine Hcl (NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).
    Efonidipine hydrochloride
  • HY-19721
    ABT-639
    2 Publications Verification

    		 Calcium Channel Neurological Disease
    ABT-639 is a novel, peripherally acting, selective T-type Ca 2+ channel blocker.
    ABT-639
  • HY-101096
    Suvecaltamide

    MK-8998

    		 Calcium Channel Neurological Disease
    Suvecaltamide (MK-8998; compound 33) is a potent and selective inhibitor of the T-type calcium channel.
    Suvecaltamide
  • HY-101616
    ABT-639 hydrochloride

    		Calcium Channel Neurological Disease
    ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca 2+ channel blocker.
    ABT-639 hydrochloride
  • HY-12502A
    Efonidipine hydrochloride monoethanolate

    NZ-105 hydrochloride monoethanolate

    		 Calcium Channel Cardiovascular Disease
    Efonidipine hydrochloride monoethanolate (NZ-105 hydrochloride monoethanolate) is a dual T-type and L-type calcium channel blocker (CCB).
    Efonidipine hydrochloride monoethanolate
  • HY-120546
    Ulixacaltamide

    Z944

    		 Calcium Channel Neurological Disease
    Ulixacaltamide (Z944) is an orally active T-type calcium channel antagonist that rescues impairments in crossmodal and visual recognition memory.
    Ulixacaltamide
  • HY-10388
    TTA-Q6
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    TTA-Q6 is a selective T-type Ca 2+ channel antagonist, which can be used in the research of neurological disease .
    TTA-Q6
  • HY-115681
    (2R/S)-6-PNG
    1 Publications Verification

    6-Prenylnaringenin; (±)-6-Prenylnaringenin

    		 Calcium Channel Neurological Disease
    (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca 2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .
    (2R/S)-6-PNG
  • HY-B1378
    Ethosuximide

    		Calcium Channel Neurological Disease Cancer
    Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
    Ethosuximide
  • HY-120597
    SAK3

    		Calcium Channel Neurological Disease
    SAK3 is a potent T-type voltage-gated Ca 2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca 2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .
    SAK3
  • HY-10388A
    TTA-Q6(isomer)

    		Calcium Channel Others
    TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective T-type Ca 2+ channel antagonist.
    TTA-Q6(isomer)
  • HY-161076
    KTt-45

    		Caspase Apoptosis Calcium Channel Cancer
    KTt-45 is a T-type calcium channel blocker. KTt-45 has anticancer effect by inducing apoptosis on HeLa cervical cancer cell line .
    KTt-45
  • HY-112723
    Apinocaltamide

    ACT-709478

    		 Calcium Channel Neurological Disease
    Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies .
    Apinocaltamide
  • HY-103309
    ML218

    		Calcium Channel Neurological Disease
    ML218 is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218
  • HY-103309A
    ML218 hydrochloride

    		Calcium Channel Neurological Disease
    ML218 hydrochloride is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .
    ML218 hydrochloride
  • HY-B1378S1
    Ethosuximide-d5

    		Isotope-Labeled Compounds Calcium Channel Neurological Disease
    Ethosuximide-d5 is deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
    Ethosuximide-d5
  • HY-111828
    TTA-A2
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
    TTA-A2
  • HY-B0358A
    Flunarizine dihydrochloride
    3 Publications Verification

    		 Calcium Channel Sodium Channel Dopamine Receptor Neurological Disease
    Flunarizine dihydrochloride is a potent dual Na +/Ca 2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .
    Flunarizine dihydrochloride
  • HY-B0358
    Flunarizine
    3 Publications Verification
    Flunarizine is a potent dual Na +/Ca 2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .
    Flunarizine
  • HY-B1378S
    Ethosuximide-d3

    		Isotope-Labeled Compounds Calcium Channel Neurological Disease
    Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel[1][2].
    Ethosuximide-d3
  • HY-W032013
    1-Octanol

    Octanol

    		 Calcium Channel Endogenous Metabolite Neurological Disease Metabolic Disease
    1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents . 1-Octanol is a highly attractive biofuel with diesel-like properties .
    1-Octanol
  • HY-P1078
    Huwentoxin XVI

    		Calcium Channel Neurological Disease
    Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI
  • HY-P1078A
    Huwentoxin XVI TFA

    		Calcium Channel Neurological Disease
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI TFA
  • HY-136909
    SR33805

    		Calcium Channel Cardiovascular Disease
    SR33805 is a potent Ca 2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca 2+ channels. SR33805 can be used for the research of acute or chronic failing hearts .
    SR33805
  • HY-W032013S
    1-Octanol-d17

    Octanol-d17

    		 Calcium Channel Endogenous Metabolite
    1-Octanol-d17 is the deuterium labeled 1-Octanol[1]. 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents[2]. 1-Octanol is a highly attractive biofuel with diesel-like properties[3].
    1-Octanol-d17
  • HY-W032013S1
    1-Octanol-d2

    Octanol-d2

    		 Calcium Channel Endogenous Metabolite
    1-Octanol-d2 is the deuterium labeled 1-Octanol[1]. 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents[2]. 1-Octanol is a highly attractive biofuel with diesel-like properties[3].
    1-Octanol-d2
  • HY-151451
    Cav 3.2 inhibitor 2

    		Calcium Channel Neurological Disease
    Cav 3.2 inhibitor 2 is a Cav3.2 T-type Ca 2+ channels inhibitor with an IC50 of 0.09339 μM under -80mV holding potential. Cav 3.2 inhibitor 2 potently suppresses T-channel-dependent somatic and visceral pain in mice. Cav 3.2 inhibitor 2 can be used for the research of intractable pain .
    Cav 3.2 inhibitor 2
  • HY-P1079
    ω-Agatoxin TK

    		Calcium Channel Neurological Disease
    ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca 2+ channel blocker. ω-Agatoxin TK inhibits the high K + depolarisation-induced rise in internal Ca 2+ in cerebral isolated nerve endings with an IC50 of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .
    ω-Agatoxin TK
  • HY-103309S
    ML218-d9

    		Calcium Channel Neurological Disease
    ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].
    ML218-d9
  • HY-147639
    Cav 2.2/3.2 blocker 1

    		Calcium Channel Neurological Disease
    Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .
    Cav 2.2/3.2 blocker 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: